"In an article published in the journal Archives of Disease in Childhood, two respiratory specialists claim that doctors are overdiagnosing asthma in children, with inhalers being prescribed needlessly.
According to Asthma UK, 1.1 mill"...
The table below describes the incidence of common adverse experiences based upon three placebo-controlled, multicenter US clinical trials of 507 patients (297 female and 210 male adults (age range 18-64)). These trials included asthma patients who had previously received inhaled beta2-agonists alone, as well as those who previously required inhaled corticosteroid therapy for the control of their asthma. The patients were treated with Azmacort (triamcinolone acetonide (inhalation aerosol)) Inhalation Aerosol (including doses ranging from 150 to 600 mcg twice daily for 6 weeks) or placebo.
Adverse Events Occurring at an Incidence of Greater Than
3% and Greater Than Placebo
|Adverse Event|| 150 mcg
| Azmacort (triamcinolone acetonide (inhalation aerosol)) Dose
300 mcg bid
| 600 mcg
|Sinusitis||5 (9%)||7 (4%)||1 (2%)||6 (4%)|
|Pharyngitis||4 (7%)||42 (25%)||10 (18%)||19 (11%)|
|Headache||4 (7%)||35 (21%)||7 (12%)||24 (14%)|
|Flu Syndrome||2 (4%)||8 (5%)||1 (2%)||5 (3%)|
|Back Pain||2 (4%)||3 (2%)||2 (4%)||3 (2%)|
Adverse events that occurred at an incidence of 1-3% in the overall Azmacort (triamcinolone acetonide (inhalation aerosol)) Inhalation Aerosol treatment group and greater than placebo included:
Metabolic and Nutrition: weight gain
Nervous system: dry mouth
Organs of special sense: rash
Respiratory system: chest congestion, voice alteration
In older controlled clinical trials of steroid dependent asthmatics, urticaria was reported rarely. Anaphylaxis was not reported in these controlled trials. Typical steroid withdrawal effects including muscle aches, joint aches, and fatigue were noted in clinical trials when patients were transferred from oral steroid therapy to Azmacort (triamcinolone acetonide (inhalation aerosol)) Inhalation Aerosol. Easy bruisability was also noted in these trials.
Hoarseness, dry throat, irritated throat, dry mouth, facial edema, increased wheezing, and cough have been reported. These adverse effects have generally been mild and transient. Cases of oral candidiasis occurring with clinical use have been reported. (See WARNINGS.) Cases of growth suppression have been reported for orally inhaled corticosteroids (see PRECAUTIONS, Pediatric Use section).
Post Marketing: In addition to adverse events reported from clinical trials, the following events have been identified during post approval use of Azmacort (triamcinolone acetonide (inhalation aerosol)) Inhalation Aerosol where these events were reported voluntarily from a population of unknown size, and the frequency of occurrence cannot be determined precisely. These include rare reports of anaphylaxis, cataracts, glaucoma and very rare reports of bone mineral density loss and osteoporosis, especially with prolonged use, which may lead to an increased risk of fractures.
Read the Azmacort (triamcinolone acetonide (inhalation aerosol)) Side Effects Center for a complete guide to possible side effects
No information provided.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 3/25/2008
Additional Azmacort Information
Azmacort - User Reviews
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Allergies & Asthma
Improve treatments & prevent attacks.